Prognosis and Diagnosis of Protein Misfolding Diseases by Seeded Aggregation in...
Prognosis and Diagnosis of Protein Misfolding Diseases by Seeded Aggregation in Microspheres
There is currently no early detection system for neurological protein misfolding disorders (such as Alzheimer's and Parkinson's diseases) that would satisfy the demands for rapid, quantitative, flexible, and reproducible assays to...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NovelTAP
Novel diagnostic Tools for Alzheimer s and Parkinson s disea...
160K€
Cerrado
EUROSPIN
European Consortium on Synaptic Protein Networks in Neurolog...
16M€
Cerrado
Oligomers
Characterising protein oligomers and their role in neurodege...
2M€
Cerrado
EQC2018-005332-P
Detección precoz de enfermedades neurodegenerativas con inmu...
67K€
Cerrado
SPIDIA
Standardisation and improvement of generic pre analytical to...
14M€
Cerrado
TOPAG
Toxic protein aggregation in neurodegeneration
14M€
Cerrado
Información proyecto BeadDiagnosis
Duración del proyecto: 18 meses
Fecha Inicio: 2015-07-07
Fecha Fin: 2017-01-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
There is currently no early detection system for neurological protein misfolding disorders (such as Alzheimer's and Parkinson's diseases) that would satisfy the demands for rapid, quantitative, flexible, and reproducible assays to study amyloidogenesis in biological samples. We will explore the potential of aggregation assays in microdroplets that are formed in microfluidic devices. We have found that the readout of this assay reflects the disease progression, when samples of Drosophila fruit fly brains and mouse brain and serum are analysed. We will use this PoC project explore the utility of this technology to report on aggregation of amyloid precursors in human biological samples, to test whether the potential of this technology extends to patients diagnosis and prognosis. Such data would resolve the question whether our early diagnosis system is immediately useful in a medical context and strengthen the case for venture capital funding.